Edition:
United Kingdom

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

23.13USD
16 Jan 2018
Change (% chg)

-- (--)
Prev Close
$23.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
689,030
52-wk High
$55.28
52-wk Low
$19.00

Select another date:

Mon, Jan 8 2018

BRIEF-Mallinckrodt Will Sell Recothrom, Preveleak To Baxter for $185 Mln

* MALLINCKRODT - TOTAL DEAL CONSIDERATION OF $185 MILLION, WITH $153 MILLION UPFRONT, INCLUDING EXISTING INVENTORY, REMAINDER IN POTENTIAL MILESTONE PAYMENTS

BRIEF-Mallinckrodt Unit Borrowed $900 Mln Under Revolving Credit Facility

* MALLINCKRODT PLC SAYS ON DEC 29 UNIT OF CO BORROWED $900 MILLION AS A REVOLVING LOAN UNDER THE REVOLVING CREDIT FACILITY -SEC FILING

BRIEF-Mallinckrodt Completes Stannsoporfin New Drug Application Filing

* MALLINCKRODT COMPLETES STANNSOPORFIN NEW DRUG APPLICATION FILING Source text for Eikon: Further company coverage:

Mallinckrodt to buy Sucampo for about $840 million

Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million (£628.8 million) to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.

Mallinckrodt to buy Sucampo for about $840 million

Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.

UPDATE 2-Mallinckrodt to buy Sucampo for about $840 mln

* Deal for $18/share, a premium of about 6 pct to Friday close

BRIEF-Sucampo Pharma Says If Merger Agreement Terminated, Co Agreed To Pay Mallinckrodt Fee Of $44 Million

* SUCAMPO PHARMACEUTICALS SAYS IF MERGER AGREEMENT TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO AGREED TO PAY MALLINCKRODT FEE OF $44 MILLION - SEC FILING Source text : (http://bit.ly/2BUtNpK) Further company coverage:

BRIEF-Mallinckrodt To Buy Sucampo Pharmaceuticals For About $1.2 Bln

* MALLINCKRODT TO ACQUIRE SUCAMPO PHARMACEUTICALS FOR APPROXIMATELY $1.2 BILLION

Mallinckrodt to buy Sucampo Pharmaceuticals for about $1.2 bln

Dec 26 Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc in a deal valued at about $1.2 billion to gain access to its constipation drug, Amitiza.

BRIEF-Mallinckrodt Says TCJA Is Expected To Have A Neutral To Slightly Positive Impact On Adj Tax Expense Of Co

* MALLINCKRODT PLC SAYS TCJA IS EXPECTED TO HAVE A NEUTRAL TO SLIGHTLY POSITIVE IMPACT ON NON-GAAP ADJUSTED TAX EXPENSE OF CO - SEC FILING

Select another date: